Category: biotech

.After announcing a phase 3 launch based on favorable midstage results, iTeos and also GSK are ultimately sharing the highlights from the stage 2 TIGIT

.Otsuka Drug’s renal ailment drug has reached the primary endpoint of a period 3 trial through demonstrating in an interim review the decline of people’

.OncoC4 is taking AcroImmune– and also its in-house clinical manufacturing capacities– under its own fly an all-stock merger.Each cancer biotechs were actually co-founded through OncoC4

.Zephyrm Bioscience is gusting toward the Hong Kong stock exchange, submission (PDF) for an IPO to money period 3 trials of its own cell therapy

.It’s an uncommonly occupied Friday for biotech IPOs, with Zenas BioPharma, MBX and also Bicara Therapeutics all going people along with fine-tuned offerings.These days’s 3

.After uncovering strategies to attack the united state public markets less than a month back, Zenas Biopharma and Bicara Rehabs have actually mapped out the

.Three months after exposing that its breathing syncytial infection (RSV) preventative antibody clesrovimab had satisfied requirements in a period 2b/3 trial, Merck is actually placing

.With its lead prospect in a phase 3 test for a rare eye cancer cells, Mood Biosciences is seeking to broaden the medicine into a

.While Windtree Rehabs has actually struggled to expand the economic origins needed to have to endure, a period 2 gain for the biotech’s top property

.At this year’s Fierce Biotech Peak in Boston, our team caught up with forerunners in the biotech sector who have been realized as previous Fierce